PD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transition

Basit Öğe Kaydı
dc.authoridSecinti, Ilke Evrim/0000-0002-8614-3971
dc.contributor.authorSecinti, Ilke Evrim
dc.contributor.authorOzgur, Tumay
dc.contributor.authorDede, Isa
dc.date.accessioned2024-09-18T20:11:36Z
dc.date.available2024-09-18T20:11:36Z
dc.date.issued2022
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives Colorectal carcinomas are the third-most common tumors in the world, and colorectal cancer ranks second in cancer-related deaths. Our aim in this study was to investigate the correlation between programmed cell death ligand 1 (PD-L1) expression and clinicopathologic parameters in colorectal carcinomas and their relationship to the tumor immune microenvironment, epithelial-mesenchymal transition (EMT), and microsatellite instability. We also investigated the predictive and prognostic role of PD-L1. Methods One hundred patients with a diagnosis of colorectal adenocarcinoma who did not receive neoadjuvant therapy were included in the study. The relationships among the altered expression of PD-L1; vimentin; E-cadherin; mismatch repair status; and pathologic microenvironmental features, including the presence of tumor budding and CD8-positive tumor infiltrating lymphocytes (TILs), were assessed. Results Increased PD-L1 expression in tumor cells was associated with increased TILs (P = .013), high histologic grade (P = .011), advanced pathologic T stage (P = .007), lymph node metastasis (P = .002), distant metastasis (P < .001), perineural invasion (P = .009), high bud score (P = .023), EMT (P < .001), and shorter disease-free survival (P = .029). Conclusions Overall, PD-L1 expression in colorectal carcinoma tumor cells is a marker of poor prognosis, and the positive correlation detected between EMT status and PD-L1 expression suggests that patients with the mesenchymal phenotype may be more likely to benefit from programmed cell death 1 protein/PD-L1 immunotherapy.en_US
dc.identifier.doi10.1093/ajcp/aqac077
dc.identifier.endpage515en_US
dc.identifier.issn0002-9173
dc.identifier.issn1943-7722
dc.identifier.issue4en_US
dc.identifier.pmid35938631en_US
dc.identifier.scopus2-s2.0-85139291918en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage506en_US
dc.identifier.urihttps://doi.org/10.1093/ajcp/aqac077
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8976
dc.identifier.volume158en_US
dc.identifier.wosWOS:000837165900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Press Incen_US
dc.relation.ispartofAmerican Journal of Clinical Pathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal canceren_US
dc.subjectEpithelial-mesenchymal transitionen_US
dc.subjectPrognosisen_US
dc.subjectProgram cell death ligand 1en_US
dc.subjectTumor buddingen_US
dc.titlePD-L1 Expression in Colorectal Adenocarcinoma Is Associated With the Tumor Immune Microenvironment and Epithelial-Mesenchymal Transitionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
5.06 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu